AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Pending Claims by Year
Pending Claims — Biocell ALCL Total Lawsuits [annual] (cases)
AbbVie Pending Claims: 150 in FY2025, up 11.1% from a year earlier.
Latest, FY2025
150
Period ended Dec 31, 2025
Change on a year earlier
+11.1%
135 in FY2024
History
2 years
Since FY2024
Sources
2
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-K Note 15 Legal Proceedings & Contingencies.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Pending Claims — Biocell ALCL Total Lawsuits [annual] (cases) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 150 | +11.1% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 135 | – | Form 10-K (filed 2025-02-14) ↗ |
Cite this data
StockData. (2026). AbbVie Pending Claims, annual FY2024–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/lit-biocell-tot
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.